The Chemours Company (NYSE:CC) Stock Rated "Hold" by Wall Street Analysts

Key Points

• Analysts are broadly neutral on Chemours: 13 analysts give the stock an average “Hold” rating, with a consensus 12-month price target of $17.73.
• Chemours’ quarterly EPS of $0.21 missed the $0.26 consensus and fell from $0.40 a year earlier, while revenue of $1.54 billion slightly beat estimates. Fourth-quarter revenue guidance of $1.7 billion–$1.8 billion is above the cited analyst consensus.
• The company launched liquid-cooling fluids aimed at AI and high-performance-computing data centers, but faces legal risk from a newly filed securities class action; the allegations have not been proven.

The Chemours Company (NYSE:CC - Get Free Report) has earned an average recommendation of "Hold" from the thirteen analysts that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and three have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $17.73.

CC has been the topic of a number of analyst reports. Royal Bank Of Canada downgraded shares of Chemours from an "outperform" rating to a "sector perform" rating and set a $14.00 price objective on the stock. in a report on Tuesday, October 13th. Zacks Research upgraded shares of Chemours from a "strong sell" rating to a "hold" rating in a report on Thursday, September 10th. Mizuho lowered shares of Chemours from an "outperform" rating to a "neutral" rating and dropped their price target for the company from $18.00 to $15.00 in a research report on Wednesday, October 14th. UBS Group dropped their price target on shares of Chemours from $18.00 to $16.00 and set a "neutral" rating on the stock in a research report on Monday, October 5th. Finally, Morgan Stanley set a $18.00 price target on shares of Chemours in a report on Monday, August 10th.

Chemours Stock Performance

Shares of Chemours stock opened at $13.09 on Wednesday. The company has a market cap of $1.97 billion, a PE ratio of -12.83 and a beta of 1.47. Chemours has a 52 week low of $10.44 and a 52 week high of $28.67. The business has a 50 day moving average price of $14.12 and a 200-day moving average price of $18.25. The company has a quick ratio of 0.88, a current ratio of 1.66 and a debt-to-equity ratio of 18.98.

Chemours (NYSE:CC - Get Free Report) last announced its earnings results on Monday, November 2nd. The specialty chemicals company reported $0.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.26 by ($0.05). The company had revenue of $1.54 billion for the quarter, compared to analysts' expectations of $1.53 billion. Chemours had a negative net margin of 2.64% and a positive return on equity of 78.76%. The firm's quarterly revenue was up 3.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.40 EPS. Equities analysts anticipate that Chemours will post 0.83 earnings per share for the current fiscal year.

Chemours Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 15th. Stockholders of record on Monday, November 16th will be paid a $0.0875 dividend. This represents a $0.35 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Monday, November 16th. Chemours's payout ratio is presently -18.32%.

More Chemours News

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Chemours launched Faizeon two-phase liquid-cooling fluids for AI and high-performance-computing data centers, targeting a growing market with products designed to reduce energy and water use. The commercial opportunity is promising, though the announcement did not quantify expected revenue. Chemours launches Faizeon cooling solutions
• Positive Sentiment: Fourth-quarter revenue guidance of $1.7 billion–$1.8 billion is above the cited analyst consensus of $1.4 billion. Full-year 2026 revenue guidance of $5.9 billion is in line with consensus. Chemours reports third-quarter results
• Neutral Sentiment: Goldman Sachs maintained a Hold rating and a $16 price target, citing strong third-quarter results but offsetting concerns about weak volumes and a cautious fourth-quarter outlook. Goldman Sachs maintains Hold rating
• Negative Sentiment: Third-quarter adjusted EPS was $0.21, missing the $0.26 consensus and down from $0.40 a year earlier. Revenue of $1.54 billion slightly exceeded the $1.53 billion estimate, but the earnings shortfall and year-over-year profit decline could keep pressure on sentiment. Chemours third-quarter earnings coverage
• Negative Sentiment: A securities class action has been filed against Chemours and certain officers over alleged misleading statements during February 20–August 4, 2026, including claims concerning Opteon demand. The allegations are unproven, but the case adds legal and reputational risk; the lead-plaintiff deadline is December 7. Class action filing announcement

Insider Activity

In other Chemours news, insider Calderon Gerardo Familiar purchased 1,935 shares of the company's stock in a transaction that occurred on Wednesday, August 12th. The shares were acquired at an average cost of $15.53 per share, for a total transaction of $30,050.55. Following the completion of the acquisition, the insider owned 58,547 shares of the company's stock, valued at $909,234.91. The trade was a 3.42% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Shane Hostetter acquired 3,350 shares of Chemours stock in a transaction on Thursday, August 6th. The stock was acquired at an average price of $14.94 per share, with a total value of $50,049.00. Following the purchase, the chief financial officer directly owned 102,698 shares in the company, valued at approximately $1,534,308.12. This trade represents a 3.37% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 8,663 shares of company stock valued at $130,601 over the last three months. Corporate insiders own 0.85% of the company's stock.

Institutional Investors Weigh In On Chemours

A number of hedge funds have recently made changes to their positions in CC. BlackRock Inc. purchased a new stake in shares of Chemours during the second quarter worth $477,769,000. Wolf Hill Capital Management LP purchased a new position in shares of Chemours in the second quarter valued at $59,698,056. Bank of New York Mellon Corp purchased a new position in shares of Chemours in the second quarter valued at $33,353,000. Legal & General Group Plc purchased a new position in shares of Chemours in the second quarter valued at $28,400,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Chemours during the 2nd quarter valued at $18,119,000. 76.26% of the stock is currently owned by institutional investors.

Chemours Company Profile

The Chemours Company NYSE: CC is a global chemistry company that develops and manufactures performance chemicals and advanced materials for industrial and consumer applications. The company serves customers in markets including automotive, construction, energy, electronics, healthcare, and general manufacturing.

Chemours operates through businesses focused on Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. Its products include titanium dioxide pigments used to provide whiteness and opacity in coatings, plastics, and paper; refrigerants and related thermal-management solutions; and high-performance fluoropolymers and specialty materials sold under brands such as Teflon™, Viton™, and Nafion™.

Headquartered in Wilmington, Delaware, Chemours serves customers globally through manufacturing facilities, research and development operations, and commercial activities across North America, Latin America, Europe, and Asia-Pacific.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.